Pregaba50 mg

Pregaba 50 mg is an anticonvulsant and neuropathic pain agent used as a first-line treatment for several chronic pain conditions, seizure disorders, and musculoskeletal syndromes. It is available in two formulations — immediate-release (film-coated capsule/tablet) and controlled-release (CR) tablet — each with distinct approved indications.

Indications for Immediate-Release (Film-Coated) Formulation

The immediate-release formulation of Pregaba 50 mg is indicated for:

• Neuropathic pain associated with diabetic peripheral neuropathy (DPN) — Relieves burning, stabbing, and tingling pain caused by diabetes-related nerve damage.
• Postherpetic neuralgia (PHN) — Manages persistent nerve pain following a shingles (herpes zoster) outbreak.
• Adjunctive therapy for partial-onset seizures — Used alongside other antiepileptic drugs in patients 1 month of age and older who have partial-onset seizures.
• Fibromyalgia — Reduces widespread musculoskeletal pain, fatigue, and sleep disturbances associated with fibromyalgia.
• Neuropathic pain associated with spinal cord injury — Addresses central neuropathic pain resulting from spinal cord damage.

Indications for Controlled-Release (CR) Formulation

The controlled-release formulation of Pregaba 50 mg is indicated for:

• Neuropathic pain associated with diabetic peripheral neuropathy (DPN)
• Postherpetic neuralgia (PHN)

Note: Pregaba 50 mg should only be taken as prescribed by a registered physician. Self-medication is strongly discouraged due to its potential for dependence and serious adverse effects.

Mechanism of Action

Pregaba 50 mg is a structural analogue of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA), but it does not exert its effects by directly binding to GABA_A, GABA_B, or benzodiazepine receptors. Instead, Pregaba 50 mg binds with high affinity to the alpha2-delta (α2-δ) subunit, an auxiliary protein of voltage-gated calcium channels, in central nervous system tissues.

By binding to the α2-δ subunit, Pregaba 50 mg reduces calcium influx into hyperexcited neurons, thereby decreasing the excessive release of excitatory neurotransmitters such as glutamate, norepinephrine, and substance P. This modulation of neurotransmitter release underlies its anti-nociceptive (pain-relieving) and antiseizure effects, although the precise mechanism has not been fully elucidated.

Pharmacokinetic Profile

• Absorption: Pregaba 50 mg is rapidly absorbed following oral administration, with peak plasma concentrations occurring within 1 hour. Oral bioavailability is ≥90% and is independent of dose.
• Distribution: The volume of distribution is approximately 0.5 L/kg. Pregaba 50 mg does not bind to plasma proteins.
• Metabolism: Pregaba 50 mg undergoes negligible metabolism in humans. Approximately 90% of an administered dose is excreted unchanged in urine.
• Elimination: The elimination half-life is approximately 6 hours. Renal clearance is the primary route of elimination, and dosage adjustments are required in patients with reduced renal function (creatinine clearance <60 mL/min).

Therapeutic Classification

Pregaba 50 mg belongs to the class of adjunct and primary anti-epileptic drugs. It is also classified as a neuropathic pain agent and is a Schedule V controlled substance in the United States due to its potential for misuse and dependence.

Route of Administration

Pregaba 50 mg is administered orally. The immediate-release capsule or tablet may be taken with or without food. The controlled-release (CR) tablet must be taken after an evening meal and should be swallowed whole — it must not be split, crushed, or chewed, as this may affect the controlled-release mechanism and increase the risk of adverse effects.

Missed Dose Instructions (CR Formulation)

• If a dose is missed after the evening meal → take it before bedtime following a snack.
• If the bedtime dose is also missed → take it following the morning meal.
• If the morning meal dose is also missed → resume the usual evening dose schedule.
• Do not double up on doses to make up for a missed one.

Discontinuation

Both the immediate-release and controlled-release formulations of Pregaba 50 mg should be gradually tapered over a minimum of 1 week when discontinuing treatment. Abrupt withdrawal may trigger increased seizure frequency, anxiety, insomnia, nausea, diarrhea, and sweating.

Drug–Drug Interactions

Pregaba 50 mg is unlikely to be involved in significant pharmacokinetic drug interactions, as it is not metabolized by liver enzymes and does not bind to plasma proteins. However, the following pharmacodynamic interactions warrant clinical attention:

• CNS depressants (opioids, benzodiazepines, sedatives, alcohol): Concomitant use may potentiate central nervous system depression, including respiratory depression, sedation, and cognitive impairment. Use with caution and monitor closely.
• Thiazolidinedione antidiabetic agents (e.g., pioglitazone, rosiglitazone): Co-administration may increase the risk of peripheral edema and weight gain. Exercise caution when using these together.
• Opioids: Combined use has been associated with increased risk of respiratory depression. Dose adjustments may be required.
• Lorazepam and other anxiolytics: Enhanced CNS depression. Monitor for excessive sedation.

Drug–Food Interactions

No clinically significant drug–food interactions have been identified with the immediate-release formulation. The controlled-release formulation should be taken with food (evening meal) to optimize absorption and reduce gastrointestinal side effects.

Drug–Alcohol Interaction

Alcohol consumption during Pregaba 50 mg therapy may significantly increase sedation and dizziness. Patients are advised to avoid or strictly limit alcohol intake during treatment.

Pregaba 50 mg is generally well tolerated, but like all medications it may cause side effects. The frequency and severity are often dose-dependent.

Common Side Effects in Adults

• Dizziness — One of the most frequently reported side effects; risk increases with higher doses.
• Somnolence (drowsiness) — May impair the ability to drive or operate machinery.
• Dry mouth
• Peripheral edema — Swelling of hands, feet, and ankles.
• Blurred vision — Including diplopia (double vision); generally resolves with dose reduction.
• Weight gain — Due to increased appetite; may require dietary management.
• Difficulty with concentration and attention — Described as "thinking abnormally."

Common Side Effects in Pediatric Patients (Partial-Onset Seizures)

• Increased weight
• Increased appetite

Serious Side Effects (Seek Immediate Medical Attention)

• Angioedema — Rapid swelling of the throat, tongue, lips, face, or neck; may compromise the airway and be life-threatening.
• Suicidal thoughts or behavior — All antiepileptic drugs, including Pregaba 50 mg, carry an increased risk of suicidal ideation. Patients and caregivers should monitor for mood changes.
• Respiratory depression — Particularly dangerous when combined with CNS depressants or in patients with pre-existing respiratory impairment.
• Severe allergic reactions — Including hives, wheezing, and dyspnea requiring emergency treatment.
• Seizure exacerbation — Rapid discontinuation may increase seizure frequency.

Use During Pregnancy

There are no adequate and well-controlled studies evaluating the safety of Pregaba 50 mg in pregnant women. Animal studies have shown evidence of fetal toxicity at doses producing plasma levels similar to those achieved in humans. Pregnant women taking Pregaba 50 mg should be counseled about the potential risk to the fetus.

Pregaba 50 mg is classified as FDA Pregnancy Category C. It should be used during pregnancy only if the potential benefit clearly justifies the potential risk to the fetus. Women of childbearing potential who are prescribed Pregaba 50 mg should use effective contraception.

Use During Breastfeeding

Small amounts of Pregaba 50 mg have been detected in the breast milk of lactating women. Due to the potential risk of tumorigenicity observed in animal studies, breastfeeding is not recommended during treatment with Pregaba 50 mg. Women who require Pregaba 50 mg therapy should consider alternative feeding options for their infants.

Angioedema

Angioedema involving the throat, head, and neck has been reported with Pregaba 50 mg and may cause life-threatening respiratory compromise. Pregaba 50 mg must be discontinued immediately if angioedema occurs. Patients with a prior history of angioedema to Pregaba 50 mg or related drugs (e.g., gabapentin) are at higher risk.

Hypersensitivity Reactions

Serious hypersensitivity reactions, including hives, dyspnea, and wheezing, have been reported. Discontinue Pregaba 50 mg immediately if these symptoms develop.

Suicidal Behavior and Ideation

Antiepileptic drugs, including Pregaba 50 mg, increase the risk of suicidal thoughts or behavior. Patients should be monitored for the emergence or worsening of depression, unusual changes in mood or behavior, or the appearance of suicidal thoughts. Caregivers and family members should be alerted to report any concerning changes to the prescribing physician immediately.

Respiratory Depression

Pregaba 50 mg may cause significant respiratory depression, especially when co-administered with opioids, CNS depressants, or in patients with underlying respiratory disease. Monitor respiratory function and adjust dosages as clinically appropriate.

Driving and Operating Machinery

Pregaba 50 mg may cause dizziness and somnolence, impairing the ability to drive vehicles or operate heavy machinery. Patients should be advised not to engage in such activities until they understand how Pregaba 50 mg affects them.

Abrupt Discontinuation

Do not stop Pregaba 50 mg suddenly. Abrupt discontinuation may cause increased seizure frequency, anxiety, insomnia, nausea, hyperhidrosis, and diarrhea. Always taper Pregaba 50 mg over a minimum of 1 week under medical supervision.

Peripheral Edema

Pregaba 50 mg may cause peripheral edema (swelling of the extremities). Caution is advised in patients with heart failure, as fluid retention may worsen their condition.

Thiazolidinedione Antidiabetic Agents

When co-administered with thiazolidinediones (e.g., pioglitazone), the risk of peripheral edema and weight gain is increased. Use this combination cautiously.

Renal Impairment

Since Pregaba 50 mg is primarily eliminated by the kidneys, dose adjustments are essential in patients with reduced renal function (creatinine clearance <60 mL/min). Patients on hemodialysis require a supplemental dose after each dialysis session.

Signs and Symptoms of Overdose

In cases of Pregaba 50 mg overdose, the following clinical signs and symptoms have been reported:

• Reduced consciousness and profound sedation
• Depression and anxiety
• Confusional state and disorientation
• Agitation and restlessness
• Seizures
• Heart block (in severe cases)

Management of Overdose

There is no specific antidote for Pregaba 50 mg overdose. Management is primarily supportive:

• If the overdose is recent and the patient is conscious, elimination of unabsorbed drug may be attempted by emesis or gastric lavage, with appropriate airway protection.
• Maintain airway patency and support respiration as needed.
• Continuous monitoring of vital signs and clinical status is essential.
• Hemodialysis effectively removes Pregaba 50 mg from the bloodstream and may be considered in severe overdose cases, especially in patients with renal impairment.
• Seek emergency medical care immediately. Contact the nearest poison control center or emergency department.

• Store below 30°C in a cool, dry place.
• Protect from direct light and moisture.
• Store in the original packaging until use.
• Keep out of the reach of children and pets.
• Do not use after the expiry date printed on the packaging.
• Do not dispose of medicines via wastewater or household waste. Return unused medicines to a pharmacy for proper disposal.

Pediatric Patients

The safety and effectiveness of Pregaba 50 mg in pediatric patients have not been established for the following conditions:

• Neuropathic pain associated with diabetic peripheral neuropathy
• Postherpetic neuralgia
• Neuropathic pain associated with spinal cord injury
• Fibromyalgia

For adjunctive therapy for partial-onset seizures, Pregaba 50 mg (immediate-release) is approved for patients 1 month of age and older. Safety and effectiveness in patients below 1 month of age have not been established.

The safety and effectiveness of the controlled-release (CR) formulation have not been established in pediatric patients of any age.

Elderly Patients

Elderly patients are more likely to have reduced renal function, which may necessitate dose adjustment. They are also at increased risk of adverse effects such as dizziness, somnolence, and peripheral edema, which may increase the risk of falls. Careful monitoring and cautious dose titration are recommended.

Patients with Renal Impairment

Pregaba 50 mg clearance is directly proportional to creatinine clearance. Dose reduction is mandatory in patients with CrCl <60 mL/min. Patients on hemodialysis require supplemental dosing following each session. Consult the prescribing information for specific dose adjustment tables.

Patients with Hepatic Impairment

Since Pregaba 50 mg undergoes negligible hepatic metabolism, no dose adjustment is required for patients with hepatic impairment.